Phase 3Active, not recruitingAge-related condition
TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration (nAMD)
A Phase III, Randomized, Multicenter, Doubled-blind Clinical Trial Comparing the Efficacy and Safety of TAB014 and Lucentis in Neovascular Age-related Macular Degeneration (nAMD) Patients
- Sponsor
- BioDlink Biopharm Co., Ltd. (Industry)
- Enrollment
- 488 planned
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- TAB014 Monoclonal Antibody Injection; Ranibizumab Injection [Lucentis]
- Ages
- adults, older adults
- Registry
- NCT05461339
Full record on ClinicalTrials.gov
From the registry
This study is a randomized, multi-center, double blind, Lucentis controlled non-inferiority study in neovascular age-related macular degeneration patients. The objective of this study is to compare the efficacy and safety of TAB014 and ranibizumab (Lucentis).
Primary outcomes
- Evaluate the change in BCVA of the study eye from TAB014 and ranibizumab treatment groups.
History
Study completion
Last registry update
Primary completion
Registered
Started